Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Recruiting · Phase 1, Phase 2 · NCT06772623
Conditions: Non Small Cell Lung Carcinoma, c-MET
At a glance
- Research payments reported, 2025
- $674,222
- U.S. investigators named
- 16
- Sites paid
- 16
- Planned or actual enrollment
- 252
About the trial
- Sponsor
- AbbVie
- Tested
- Telisotuzumab Adizutecan (drug), Budigalimab (drug), Pembrolizumab (drug), Pembrolizumab (drug), Carboplatin (drug), Pemetrexed (drug), Cisplatin (drug)
- Dates
- Started 2025-03-06; completion 2027-11
- Results posted
- Not yet
Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide. The purpose of this study is to assess adverse events and change in disease activity when Telisotuzumab Adizutecan (ABBV-400) is given in combination with a programmed cell death receptor 1 (PD1) immune checkpoint inhibitor to adult participants to treat NSCLC. Telisotuzumab Adizutecan (ABBV-400) and budigalimab are investigational drugs being developed for the treatment of NSCLC. This study will be divided into two stages, with the first stage treating participants with several doses of telisotuzumab adizutecan in combinatio…
From ClinicalTrials.gov, last updated 2026-10-27. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $674,222 in research payments for this study in 2025 (71 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Nawazish A. Khan, MD Medical Oncology · Cerritos, CA
- David J. Park, M.D. Medical Oncology · Fullerton, CA
- David Camidge, MD Medical Oncology · Aurora, CO
- Robert M. Jotte, MD Hematology & Oncology · Lone Tree, CO
- Patricia L. Rich, MD Medical Oncology · Atlanta, GA
- Srilata Gundala, M.D. Hematology & Oncology · Hinsdale, IL
- Nikhil A. Shukla, M.D. Medical Oncology · Indianapolis, IN
- Siu-long Yao, M.D. Hematology & Oncology · East Brunswick, NJ
- Richard M. Zuniga, MD Hematology & Oncology · Babylon, NY
- Afshin Dowlati, MD Hematology & Oncology · Cleveland, OH
- Hayman S. Salib, MD Hematology & Oncology · Easton, PA
- Maria V. Garcia Pallas, M.D. Hematology & Oncology · Guaynabo, PR
- Mayra Rivera Figueroa, M.D. Hematology & Oncology · Rio Piedras, PR
- Murtaza N. Bhuriwala, MD Medical Oncology · Tomball, TX
- Shiven Patel, MD, MBA, FACP Hematology & Oncology · Salt Lake City, UT
- Joseph Z. Ye, MD, PHD Medical Oncology · Olympia, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Titan Health PArtners LLC $111,041
- North Shore Hematology $95,012
- Pan American Center for Oncology $77,874
- University of Utah Hospital and Clinics, UT $64,006
- Uh Cleveland Medical Center, OH $48,580
- The Regents of the Univ of Colorado $45,889
- Spoknwrd Clinical Trials Inc $44,940
- Hope and Healing Cancer Services L $28,590
- Fomat Medical Research Inc $24,950
- Millenium Research & Clincal $23,706
- Providence Medical Foundation $21,544
- Community Hospital East, IN $21,099
- Rocky Mountain Cancer Centers $20,000
- American Oncology PArtners PA $16,490
- Parkview Regional Medical Center, IN $16,000
- Hosa LLC $13,050
- $1,450
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.